Skip to content
Yog Pharma
CardiovascularAngiotensin II receptor blocker (prodrug)

Olmesartan Medoxomil is an angiotensin II receptor blocker (prodrug) indicated for hypertension. We supply it to US manufacturers of tablets and fixed-dose combinations.

CAS144689-63-4558.6 g/molC29H30N6O6
2D structure of Olmesartan Medoxomil.

Data from PubChem (CID 130881) and FDA’s substance registry

CAS number

144689-63-4

Molecular formula

C29H30N6O6

Molecular weight

558.6g/mol

FDA UNII

IUPAC name

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

InChIKey

UQGKUQLKSCSZGY-UHFFFAOYSA-N

Appearance
White to off-white powder.
Solubility
Practically insoluble in water and sparingly soluble in methanol.

Typical description, from FDA-approved labeling and pharmacopoeial monographs. The specification sent with your quote is the controlling document for any source.

Worth settling with your inquiry

A tetrazole sartan and an ester prodrug. Ask for nitrosamine and azido impurity data, and for the limit on olmesartan free acid, its main hydrolysis product.

On the US market

Reference product
BenicarNDA 021286
Approved ANDAs
18 with a marketed product
Approved forms and strengths
  • Tablet 5 mg, 20 mg, 40 mg

Single-ingredient products in FDA’s Drugs@FDA database, retrieved November 2026. The brand name belongs to its owner and identifies the reference product only.

Grade

USP or Ph. Eur. where a monograph exists, or your own specification.

Quantities

From development quantities for formulation work to commercial supply.

Packaging

To the manufacturer’s standard, typically fiber or HDPE drums with double polyethylene liners.

Regulatory filings

US DMF and CEP availability depends on the source. We confirm the filing status in writing with the quotation.

Documents available with a quote

  • Specification and certificate of analysis
  • Safety data sheet
  • Method of analysis
  • DMF letter of authorization, where a US DMF is filed
  • GMP certificate and inspection history of the site
  • Residual solvents and elemental impurities statements
  • Nitrosamine risk assessment
  • TSE/BSE statement

Need something else for your QA file? Email info@yogpharma.com